( click to enlarge )
Gogo Inc (NASDAQ:GOGO) made a new 52
week high last week spiking up to 22.05 and surpassing the previous
high set in March. The stock has had a very strong move from the
mid-January low and remains in a strong uptrend on the daily charts.
Yesterday's drop on low volume should not be interpreted as the start of
a sell-off. Might form a cup and handle pattern here. MACD and A/D both
signal positive strength and accumulation. The stock is trading above
all major EMAs, also a bullish sign.
( click to enlarge )
Oncolytics Biotech, Inc.
(NASDAQ:ONCY) The stock Friday surged 10% or 7 cents to 76c per share on
high volume as the company announced that the U.S. FDA has granted an
Orphan Drug Designation for its lead product candidate, REOLYSIN, for
the treatment of malignant glioma. From a technical standpoint, the
stock seems to have broken a falling wedge pattern, which often precedes
reversals. In addition, technical indicator MACD is on the cusp of a
bullish crossover showing the stock is heading towards a bull market.
The 14-day RSI is also back above 50. Yesterday's good news should push
stock prices back up. Im long with an initial target of 93c then 1.10.
( click to enlarge )
Sonus Networks, Inc. (NASDAQ:SONS)
has seen a massive drop in share price and I’m starting to see more
evidences on charts, supporting the idea that a bounce here is becoming
likely. With the daily momentum indicators showing positive divergences I
think a push to $8.90 or better could be in the making. Be patient.
( click to enlarge )
Rosetta Genomics Ltd. (NASDAQ:ROSG)
Price targets are rising again and the stock got two upgrades last week,
from Zacks ($13) and Cantor ($5.50), both buy ratings and estimates are
on the rise. I expect more in the coming weeks. The stock closed the
week above the pivot at $3.84. Further strength cannot be ruled out now.
( click to enlarge )
Second Sight Medical Products Inc
(NASDAQ:EYES) The potential for this company/stock is enormous IMHO.
From my point of view, their revolutionary products could create
meaningful shareholder value in the next months. The company has a
dominant patent portfolio with nearly 300 granted patents and over 150
pending patent applications and has no direct competitors in its niche.
From a technical standpoint, the bulls remain in control with price
trading above all key EMA's while MACD still in a buy setup. Im long.
( click to enlarge )
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)
The stock resumed a fresh up move after basing for two weeks and seems
poised for a breakout above the 12.20 level. The recent high volume
activity along with positive crossover of MACD on the daily charts
suggest fresh buying interest in the stock. This will be a stock to
watch next week.
( click to enlarge )
Arena Pharmaceuticals, Inc.
(NASDAQ:ARNA) The stock has been trading sideways for the last few weeks
and is showing signs of bullishness. The MACD had a positive crossover
last week and the RSI remains in buy mode that supports the positive
momentum in the stock. Buy signal: When stock breaks $4.79 on volume.
No comments:
Post a Comment